Reports

Tailored and reduced clinical programme for biosimilars

Home/Reports | Posted 10/02/2017

The European Medicines Agency (EMA) is constantly issuing new guidelines and updating its existing guidelines based on new evidence and rapid advances in analytical sciences. Dr Martina Weise, Head of the Licensing Division at the Federal Institute for Drugs and Medical Devices (BfArM), discussed tailored and reduced clinical programme for biosimilarsin the European Union (EU) in her presentation [1] at the 14th Annual Biosimilar Medicines Group Conference.

Changes in quality data and non-clinical studies for biosimilars

Home/Reports | Posted 03/02/2017

Since it first developed guidelines for the approval of biosimilars via an abbreviated registration process during 2005 to 2006, the European Medicines Agency (EMA) has issued new guidelines and updated its existing guidelines based on new evidence and rapid advances in analytical sciences. In her presentation [1] at the 14th Annual Biosimilar Medicines Group Conference, Dr Martina Weise, Head of the Licensing Division at the Federal Institute for Drugs and Medical Devices (BfArM), discussed the changes in data requirements introduced in the European Union (EU).

Changes in requirements for reference products for biosimilars

Home/Reports | Posted 20/01/2017

In her presentation [1] at the 14th Annual Biosimilar Medicines Group Conference, Dr Martina Weise, Head of the Licensing Division at the Federal Institute for Drugs and Medical Devices (BfArM), discussed the changes in data requirements introduced in the European Union (EU) since it first developed guidelines for the approval of biosimilars via an abbreviated registration process during 2005 to 2006.

Pivotal clinical trials for adalimumab biosimilars

Home/Reports | Posted 28/08/2015

Biosimilars of AbbVie’s Humira (adalimumab), a human monoclonal antibody, are currently under development.

Biosimilars could save US$44.2 billion over 10 years

Home/Reports | Posted 09/01/2015

Introducing biosimilars of complex biologicals used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologicals in the US by US$44 billion over the next decade, according to an analysis carried out by the RAND Corporation.

Biosimilars applications reviewed in the EU

Home/Reports | Posted 06/01/2017

The European Union (EU) was the first to establish a legal framework for biosimilars back in 2003 [1]. Since the European Medicines Agency (EMA) approved its first biosimilars in 2006 the agency has issued new guidelines and updated its existing guidelines based on new evidence and rapid advances in analytical sciences [2].

Demonstrating biosimilarity in the EU

Home/Reports | Posted 09/12/2016

How has the European Medicines Agency (EMA) changed its requirements for biosimilars since it first approved biosimilars in 2006? This is a question raised by Dr Martina Weise, Head of the Licensing Division at the Federal Institute for Drugs and Medical Devices (BfArM).

Joint GMP inspections by EMA and FDA discussed as part of TTIP

Home/Reports | Posted 02/12/2016

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) could be carrying out joint inspections for good manufacturing practices (GMPs) as early as January 2017.

Transparency and quality characteristics for biosimilars

Home/Reports | Posted 18/11/2016

Under the auspices of increased transparency for biosimilars the European Medicines Agency (EMA) has outlined the different means available for publishing quality information on biosimilars.

The role of the IPRF in transparency for biosimilars

Home/Reports | Posted 11/11/2016

The purpose of the International Pharmaceutical Regulators Forum (IPRF) is to create an environment for pharmaceutical regulators to exchange information on issues of mutual concern and to foster regulatory cooperation. The organization’s Biosimilars Working Group (BWG) is one of five working groups that have been established to address specific issues.